Skip to main content

New This Week

Measure Summaries

American Society of Hematology Get Alerts

  • NQMC:011022
  • Feb 2017

Myelodysplastic syndromes (MDS): percentage of higher-risk MDS patients receiving azacitidine or decitabine. This updates a previously published measure summary.

About NQMC Measure Summaries

NQMC provides structured summaries containing information about measures and their development.

Submit Measures

Learn how to submit your evidence-based measures.